BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended March 2024, BioMarin Pharmaceutical (BMRN) reported revenue of $648.83 million, up 8.8% over the same period last year. EPS came in at $0.71, compared to $0.60 in the year-ago quarter.The reported revenue represents a surprise of -0.14% over the Zacks Consensus Estimate of $649.75 million. With the consensus EPS estimate being $0.60, the EPS surprise was +18.33%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...